undamentalytics Newsletter
Sign in

Arbutus Biopharma Corp balance sheet

At the end of fiscal 2025, Arbutus Biopharma Corp had total assets of $94.6m, total liabilities of $18.0m and shareholders' equity of $76.6m. It held $18.0m in cash against $0 of debt: net cash of $18.0m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash and equivalents947697216723543732521093126361819
Receivables——02100111112210
Total current assets——701161841331291299412816115113212794274
Goodwill———01632424220———————
Total assets——7211871227623722810613720419514413295274
Deferred revenue (current)——361030——0161280—
Total current liabilities——1320111115118101133221663
Long-term debt——————————000000
Total debt0000000000000000
Total liabilities——13301657355283335355938341815
Shareholders' equity5415988548203182200731021691371069777259
Net debt (negative = net cash)−9−47−69−72−167−23−54−37−32−52−109−31−26−36−18−19
Shares outstanding24m29m—45m55m55m55m56m65m90m—157m170m190m193m198m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: ABUS vs URGNABUS vs NUVBABUS vs VALNABUS vs IBRX

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Arbutus Biopharma Corp's SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Arbutus Biopharma Corp.